Activation of EGFR and c-Met Signaling Pathways in Well-Differentiated Neuroendocrine Tumors of the Small Intestine Abstract #509

Introduction: The biological mechanisms driving midgut carcinoid (MGC) are unknown. The purpose of this study is to explore the role of EGFR and c-Met signaling pathways in the pathogenesis.
Aim(s): To determine the presence of activated EGFR and c-met in MGC.
Materials and methods: A tissue microarray of primary and metastatic MGCs was evaluated by immunohistochemistry for expression of amphiregulin, Her2/neu, EGFR, phosphorylated –EGFR (p-EGFR), c-Met and phosphorylated c-Met (p-c-Met). The microarray contains nine cases with primary SI-NET and liver metastasis, 20 with primary tumor only, and six with liver metastasis only. Activation of EGFR and c-Met was compared between the primary tumors and liver metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Eric Liu

To read results and conclusion, please login ...

Further abstracts you may be interested in

#508 Differential Expression of Markers in a Midgut Carcinoid Tissue Microarray
Introduction: Molecular mechanisms driving well-differentiated midgut carcinoid (MGC) tumors are not well-established. To pursue higher resolution tumor diagnostics, we studied a panel of markers for their expression in MGC, including: serotonin, FGF2, b-catenin, and E-cadherin, in primary, lymph node, and liver metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Eric Liu
#3030 Targeting CXCR4 and Thioredoxin Reductase in Theranostics of Atypical Carcinoid and Neuroendocrine Carcinoma
Introduction: Atypical carcinoid and small cell lung cancer (SCLC) are currently incurable. There is thus a critical need for new diagnostic and therapeutic strategies for lung neuroendocrine neoplasms (LNEN). Chemokine receptor 4 (CXCR4), a G protein coupled receptor and theranostic target, plays a crucial role in metastases of LNEN. We hypothesize combination of thioredoxin reductase (TR) inhibitor represents a metabolic strategy to enhance cytotoxicity in peptide-receptor radionuclide therapy (PRRT) of LNEN.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dijie Liu
#3003 The Proinflammatory Molecule, VAP-1, Is Enriched in the Stroma of Midgut NETs and Plaques of Carcinoid Heart Disease Valves
Introduction: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Chris Weston
Authors: Shah T, Sagar V, Neil D, Liu B, ...
#654 Identification of Signaling Pathways Involved in Lung Carcinoid Progression Using Gene Expression Profiling
Introduction: Lung carcinoids are well-differentiated neuroendocrine tumors (NETs) usually associated with a favorable prognosis. Mechanisms underlying progression are poorly understood.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MSc Dorian Swarts
#88 EpCam expression and detection of circulating tumor cells in neuroendocrine tumors
Introduction: Using the CellSearchTM system, circulating tumor cells (CTCs) can be reproducibly enumerated according to expression of EpCAM and cytokeratins 8, 18 or 19 and the absence of the haemopoietic marker CD45. The number of CTCs detected in 7.5 mls blood has been shown to correlate with prognosis in breast, colon and prostate cancer and can predict response to therapy. Neuroendocrine tumors (NETs) have not previously been reported to express EpCAM and have not been systematically assessed for presence of CTCs. We have therefore explored the expression of EpCAM in NETs and the detection of NET cells in the circulation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan